New research reveals misinformation’s real-world impact, including poor health outcomes, falling public trust, and significant societal harm.
Articles on Hydroxychloroquine
Displaying 1 - 20 of 38 articles
A new study shows that omicron may have changed the way it enters our cells.
Ivermectin has been a lifesaving drug for people with parasitic infections like river blindness and strongyloidiasis. But taking it for COVID-19 may result in the opposite effect.
As more people become vaccinated, many of them are eager to resume their social lives. And yet, many are fearful, and some may not want to return to life as they previously experienced it.
The global pandemic has fueled illicit online sales of COVID-19 commodities, some of which are dangerous or illegal. Researchers are assessing the size and reach of this underground market.
Stella Immanuel, who made headlines recently regarding a false coronavirus cure claim, has many beliefs related to how demons are a threat to humans. An expert explains their long religious history.
A new study not only shows that the malarial drug chloroquine doesn’t block SARS-CoV-2 from infecting lung cells, but also explains why.
When news reports tout a drug, people get interested, even if the benefits are unproven. Patient hopes, requests and demands can easily turn into real prescriptions in their doctor’s office.
The h-index has become an indicator of quality for many researchers and may influence the allocation of research funds. But some question its value.
Severe scrutiny of two major papers, including one about the effectiveness of hydroxychloroquine, is part of science’s normal process of self-correction.
During the last six months, news reports have mentioned dozens of drugs that may be effective against the new coronavirus. Here we lay out the evidence and reveal which ones are proven to work. Or not.
Scientists have discovered that a widely used, cheap steroid can fight off COVID-19 in the most severe cases. Here’s how it works.
In this week’s round-up of coronavirus articles by scholars around the globe, we explore the disproportionate impacts of COVID-19 and the latest on drug trials.
The FDA has sped up its approval process for coronavirus treatments, creating a new division to expedite the regulatory process. But is safety being sidelined for speed?
Our experts look at why people of colour are being hit harder by COVID-19, New Zealand’s success in eliminating the virus, and the latest on drug trials.
In the hope of finding a cure for COVID-19, it is easy to get lost in the hype. But chloroquine and hydroxychloroquine should for now be set aside.
People taking hydroxychloroquine for coronavirus may be more likely to die, according to new research. But that doesn’t mean the drug is killing them.
Our expert assessed all the controlled studies so far on hydroxychloroquine. His findings may surprise you.
Africa needs to be better prepared to deal with future pandemics. That should start with a re-assessment of how countries invest in – and support – local research.
The US president has reignited controversy over the use of malaria drugs to guard against COVID-19. But there is little reliable evidence so far that this tactic is safe or effective.
Top contributors
-
Professor of Chemistry and Biochemistry and President-Elect of the International Society for Antiviral Research, University of Maryland, Baltimore County
-
Professor of Medicine, University of Pittsburgh
-
Research Assistant Professor, Division of Medical Ethics, New York University
-
Associate Professor of Pharmacy, University of Connecticut
-
Associate Professor, University of Minnesota Center for Bioethics, School of Public Health, & College of Pharmacy, University of Minnesota
-
Senior Lecturer in Chemical Pathology, University of Westminster
-
Associate Professor of Dermatology and Human Health; Herbarium Curator, Emory University
-
Professor of Religion and Classics, USC Dornsife College of Letters, Arts and Sciences
-
Senior Lecturer in Pharmacology, Adelaide University
-
Professor of Law, Boston University
-
Emergency Physician and Clinician Scientist, University of Toronto
-
Postdoctoral Researcher, Immunology and Virology, University of Cambridge
-
Head of School and Dean of Pharmacy, University of Sydney
-
Associate Professor, Faculty of Law and Cumming School of Medicine; Member, AMR One Health Consortium, University of Calgary
-
Professor Emeritus of Biochemistry, University at Buffalo